|Julie R Gralow, MD
Associate Professor, Medical Oncology
University of Washington and
Fred Hutchinson Cancer Research Center
|John F R Robertson, MD
Professor of Surgery
Head of Academic Division of
University of Nottingham City Hospital
Nottingham, United Kingdom
|Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering Cancer Center
New York, New York
|George W Sledge Jr, MD
Ballve-Lantero Professor of Oncology
Professor of Medicine and Pathology
Indiana University School of Medicine
|Edith A Perez, MD
Professor of Medicine
Mayo Medical School
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program, Division
of Hematology and Oncology, Mayo Clinic
|Norman Wolmark, MD
Professor and Chairman
Department of Human Oncology
Allegheny General Hospital
Professor, Drexel University
College of Medicine
Chairman, National Surgical
Adjuvant Breast and Bowel Project
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc; Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Gralow — Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech Inc, Roche Laboratories Inc. Dr Hudis — Consulting Fees: Amgen Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Genentech Inc; Ownership Interest: Genomic Health Inc. Dr Perez — Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech Inc, Eli Lilly and Company, Pfizer Inc, Sanofi-Aventis. Dr Robertson — Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc, Schering AG; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Schering AG. Dr Sledge — Consulting Fees: Genentech Inc, Roche Laboratories Inc; Contracted Research: Sanofi-Aventis. Dr Wolmark — Consulting Fees: Sanofi-Aventis.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
Let’s get this thing done.
Breast Cancer Clinical Trials: